Another possibility is the use of dupilumab (IL-4/IL-13 receptor blocker), which has shown promising results in the treatment of various eosinophil-associated diseases including atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis (232, 233). The gene discussed is IL4; the disease is nasal cavity polyp.